[New targeted therapies in breast cancer]

Gynecol Obstet Fertil. 2014 Nov;42(11):787-94. doi: 10.1016/j.gyobfe.2014.09.007. Epub 2014 Oct 19.
[Article in French]

Abstract

Trastuzumab improves care of patients with HER2+ breast cancer and allows a major gain in terms of survival. T-DM1 and pertuzumab are two new treatments, which give very encouraging results in metastatic breast cancer. Their place in neo-adjuvant and adjuvant setting still remains to be defined. Bevacizumab have its place in metastatic breast cancer. In adjuvant setting, results are disappointing and in neo-adjuvant setting, we need more studies on subgroups, which can benefit more. Development of the PARP inhibitors was slowed down by recent negative results in metastatic breast cancer but studies continue with more targeted patient's. Finally, everolimus, inhibitor of mTOR, allows to by pass the hormono-resistance in metastatic phase. Its toxicity must be taken into account in particular in adjuvant setting.

Keywords: Breast cancer; Cancer du sein; Survie; Survival; Targeted therapies; Thérapies ciblées.

Publication types

  • Review

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab / therapeutic use
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Drug Delivery Systems
  • Female
  • Humans
  • Lapatinib
  • Maytansine / analogs & derivatives
  • Maytansine / therapeutic use
  • Neoadjuvant Therapy
  • Neoplasm Metastasis / drug therapy
  • Neovascularization, Pathologic / drug therapy
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Quinazolines / therapeutic use
  • Receptor, ErbB-2 / analysis
  • Receptor, ErbB-2 / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Trastuzumab / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Quinazolines
  • Lapatinib
  • Maytansine
  • Bevacizumab
  • MTOR protein, human
  • Receptor, ErbB-2
  • TOR Serine-Threonine Kinases
  • pertuzumab
  • Trastuzumab
  • Ado-Trastuzumab Emtansine